The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis.

Clicks: 322
ID: 67530
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Jigar Raythatha has spent nearly 20 years in the biotechnology industry in a variety of business functions. He rejoined Constellation in March 2017 as the company's Chief Executive Officer, from Jounce Therapeutics, where he held the role of the Chief Business Officer. At Jounce, Jigar was the first employee and helped build the company from its inception to a 100-person, publicly traded research and development organization. Previously, he served as the head of the corporate development at Constellation, where he led business development, strategy, and program and alliance management functions. Prior to his first stint at Constellation, Jigar worked with Red Abbey Venture Partners. Earlier in his career, Jigar held roles of increasing responsibility at Biogen and A.T. Kearney. He earned an MBA from Columbia University and a BA in biochemistry and economics from Rutgers University.
Reference Key
raythatha2019theepigenomics Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Raythatha, Jigar;Arnold, Lauren;
Journal epigenomics
Year 2019
DOI
10.2217/epi-2019-0274
URL
Keywords
clinical trials prostate cancer therapeutics epigenetics bet cpi-0610 ezh2 pathway epigenomics myeloidfibrosis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.